Reintroducing
About us / Press room
News about our community
Our actions match our words
August 7, 2019
ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR IDP-123 TREATMENT FOR ACNE VULGARIS IN LOTION FORM

PDUFA Action Date is Dec. 22, 2019

RALEIGH, N.C., Aug. 7, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the world, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-123 (tazarotene 0.045%) Lotion with a PDUFA action date of Dec. 22, 2019. If approved, IDP-123 will be the first tazarotene acne treatment available in a lotion form.

“Millions of Americans are affected by acne and, for many of these patients, it can be difficult to find a treatment that works for them,” said Bill Humphries, president, Ortho Dermatologics. “If approved, IDP-123 will offer physicians and their patients a lower concentration of tazarotene in a lotion formulation, helping to further expand upon our growing portfolio of acne treatments.”

August 1, 2019
ORTHO DERMATOLOGICS ANNOUNCES CASH-PAY PRESCRIPTION PROGRAM, DERMATOLOGY.COM, TO BE AVAILABLE AT WALGREENS STORES NATIONWIDE

Dermatology.com Supports Lower, Predictable Pricing for Many of Ortho Dermatologics’ Prescription Dermatology Products at Walgreens’ 9,500 Retail Pharmacies

RALEIGH, N.C., Aug. 1, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), and Walgreens have made a modification to their existing fulfillment agreement to bring patients lower prices, increased transparency and convenience for many of Ortho Dermatologics’ dermatology products. Under the expanded agreement, Walgreens patients will have access to the select dermatology products included in Ortho Dermatologics’ first-of-its-kind cash-pay prescription program, Dermatology.com, at lower flat cash rates ranging from $50-$115. The program, which was first launched in March 2019, will be available at more than 9,500 Walgreens U.S. retail pharmacy locations by the end of August 2019.

“We launched Dermatology.com to provide patients with direct access to proven, branded dermatology medicines at predictable prices,” said Bill Humphries, president, Ortho Dermatologics. “Through this new expanded relationship with Walgreens, patients using the program will now have a nationwide pharmacy option that is not only welcoming and accessible, but will provide them with the confidence that the cost they discuss with their physician will be what they pay at the pharmacy. Together, we will continue to strive to deliver on our commitment to provide the best possible access and experience for patients who need these therapies.”

June 25, 2019
ORTHO DERMATOLOGICS ANNOUNCES U.S. LAUNCH OF DUOBRII™ (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION 0.01%/0.045% FOR PLAQUE PSORIASIS IN ADULTS

RALEIGH, N.C., June 25, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration on April 25, 2019, DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation.

“The launch of DUOBRII marks the fifth innovative therapy that Ortho Dermatologics has brought forward within the last 30 months,” said Bill Humphries, president, Ortho Dermatologics. “The DUOBRII formulation brings together two well-known ingredients in a unique lotion vehicle with low concentrations of halobetasol propionate and tazarotene, into a single, first-of-its-kind topical treatment. We are proud to provide plaque psoriasis patients this important new option, which offers strong efficacy and an extended duration of use in an advanced once daily lotion that can be dosed to clearance.”

April 25, 2019
ORTHO DERMATOLOGICS RECEIVES FDA APPROVAL OF DUOBRII™ (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION 0.01%/0.045% FOR PLAQUE PSORIASIS IN ADULTS

First and Only Topical Lotion Combining Halobetasol Propionate and Tazarotene in One Formulation1

Safety was Established in a Long-Term Study of Up to 24 Weeks of Continuous Use and up to 52 Weeks of As-Needed Use2

RALEIGH, N.C., Apr. 25, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the world, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults.1 DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation. In a year-long safety study, patients used DUOBRII Lotion for up to 24 weeks of continuous use and up to 52 weeks of as-needed use.2 DUOBRII is expected to be available in June 2019.

1. DUOBRII™ [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC.
2. Lebwohl, M.G. et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. Journal of Americal Academy of Dermatology. 2019 Jan;80(1):282-285.

March 11, 2019
ORTHO DERMATOLOGICS LAUNCHES 2019 ASPIRE HIGHER SCHOLARSHIP PROGRAM FOR STUDENTS WITH DERMATOLOGIC CONDITIONS

Students Can Apply for the Scholarship Through April 26, 2019

RALEIGH, N.C., March 11, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total in scholarships to nine students who have been treated for a dermatologic condition.

February 28, 2019
ORTHO DERMATOLOGICS TO PRESENT NEW ANALYSES AT THE AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING

10 Poster Presentations Include New Analyses of Phase 3 Data on Investigational Drug DUOBRII™ 1 and SILIQ™

RALEIGH, N.C., Feb. 28, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of 10 posters during the American Academy of Dermatology Annual Meeting in Washington, D.C., March 1-5, 2019.

February 27, 2019
ORTHO DERMATOLOGICS LAUNCHES FIRST CASH-PAY PRESCRIPTION PROGRAM IN DERMATOLOGY

Program Will Increase Patient Access to High Quality Dermatology Brands for Certain Conditions That Typically Face Insurance Challenges and High Prescription Costs
No Insurance, Copays, or Prior Authorizations Needed

RALEIGH, N.C., Feb. 27, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced today the launch of an innovative cash-pay prescription program that will make many branded products available directly to patients with a valid prescription only – no insurance, co-pays or prior authorizations needed. The program is specifically designed to provide physicians and patients with direct access to a range of proven treatment options for certain disease states that typically encounter insurance coverage hassles and high prescription costs including acne, actinic keratosis (AK), superficial basal cell carcinoma (sBCCs), barrier repair (e.g. eczema treatments), wounds and corticosteroid-responsive diseases (CRDs) like rashes, psoriasis, and atopic dermatitis (AD).

November 7, 2018
ORTHO DERMATOLOGICS ANNOUNCES U.S. LAUNCH OF BRYHALI™ (HALOBETASOL PROPIONATE) LOTION, 0.01%, FOR PLAQUE PSORIASIS IN ADULTS

Launch Expected to Occur Later this Month Following Final FDA Approval

RALEIGH, N.C., Nov. 7, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced it expects to start distribution of BRYHALI™ (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for BRYHALI Lotion on Nov. 6, 2018. BRYHALI Lotion, which is indicated for the topical treatment of plaque psoriasis in adult patients, is a new potent to superpotent corticosteroid in a novel vehicle lotion with safety established for dosing up to eight weeks.1

1. BRYHALI™ [prescribing information]. Bridgewater, NJ: Ortho Dermatologics.

October 30, 2018
ORTHO DERMATOLOGICS LAUNCHES ALTRENO™ (TRETINOIN) LOTION, 0.05% IN THE UNITED STATES

RALEIGH, N.C., Oct. 30, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of ALTRENO™ (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO Lotion is the first and only tretinoin available in a lotion for acne. ALTRENO Lotion has been shown to be effective and generally well-tolerated, and is provided in a formulation with known moisturizers hyaluronic acid, glycerin and collagen.1

1. ALTRENO™ [prescribing information]. Bridgewater, NJ: Ortho Dermatologics.

October 15, 2018
ORTHO DERMATOLOGICS TO PRESENT NEW SCIENTIFIC DATA DURING THE FALL CLINICAL DERMATOLOGY CONFERENCE

16 Poster Presentations Include New Evaluations of Investigational and Existing Products

RALEIGH, N.C., Oct. 15, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of 16 posters during the Fall Clinical Dermatology Conference in Las Vegas, Oct. 18-21. The presentations will feature new analyses of the investigational drug DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) Lotion—including long-term evaluations of safety and maintenance of treatment success—as well as new data on SILIQ™ (brodalumab) injection, ALTRENO™ (tretinoin) Lotion, 0.05%, and BRYHALI™ (halobetasol propionate) Lotion, 0.01%, which received tentative approval from the U.S. Food and Drug Administration (FDA) on Oct. 8, 2018. Please see below for SILIQ boxed warning about suicidal ideation and behavior.

1 – Provisional Name

X
X
X